OpenAI’s $80 Billion Gamble Hinges on a CEO the Board Couldn’t Trust
The New Yorker’s 18-month investigation into Sam Altman doesn’t just question his truthfulness. It exposes a company carrying financial commitments so large that some board members called them risky — all while the man in charge may have repeatedly misled the very people supposed to oversee him. OpenAI is no longer a nonprofit research lab.
That shift is now the central fact of its existence. The investigation, built on internal documents, notes from co-founder Ilya Sutskever, material from executive Dario Amodei, and more than 100 interviews, traces how the organization accelerated development, cut safety teams, and chased commercial scale.
The result: a structure where billions in outside money rest on governance that, by the reporting’s account, failed to catch Altman giving incorrect information about safety approvals and legal opinions that simply did not exist. The stakes are concrete. OpenAI currently carries financial obligations that some inside the boardroom viewed as dangerous.
Those commitments are not abstract. They are real contracts, real spending, real promises to investors.
If the board could not reliably fact-check its own CEO on matters of safety and legal standing, what exactly are those commitments backed by? Altman’s alleged misrepresentations were not minor. The New Yorker’s sources describe instances where he referenced approvals that were never granted and legal opinions that were never written.
To a board, such things are not administrative slip-ups. They are the difference between knowing whether the company is compliant with its own safety protocols and flying blind. They are the difference between informed consent from directors and rubber-stamping whatever the CEO wants.
The investigation does not claim Altman acted maliciously. It reports what he said and what the documents show.
That gap — between his statements and reality — is the problem. OpenAI has defended its leadership before. After an earlier boardroom crisis, the company issued statements backing Altman.
But the New Yorker’s reporting suggests the pattern of incorrect information predated that crisis and may have contributed to it. Sutskever, who helped found the company and later led the effort to oust Altman, kept notes that the investigation drew on.
Amodei, who left to start rival Anthropic, provided material as well. Both men were inside the room. What is genuinely at risk here is not just Altman’s job.
It is the premise that OpenAI can be trusted to safely develop technology powerful enough to reshape industries — and possibly society. The company’s original mission statement promised broad benefit, not rapid profit. The investigation tracks how that promise eroded as development sped up and the safety teams shrank.
Financial pressure does that. When a startup carries heavy commitments, speed becomes the priority.
Caution becomes a cost. And a CEO who tells the board what it wants to hear, rather than what is true, becomes a liability the company may not be able to afford. The New Yorker’s piece is one more data point in a growing stack.
Regulators, investors, and the public are all watching how OpenAI governs itself. If the board could not catch false statements about safety approvals, what else has slipped through?
That question will not go away. It follows the money. And the money is enormous.
